Research programme: cancer therapeutics - Perseis Therapeutics
Alternative Names: NNZ 8000Latest Information Update: 29 Oct 2014
At a glance
- Originator Neuren Pharmaceuticals
- Developer Perseis Therapeutics
- Class Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Breast cancer
Most Recent Events
- 28 Aug 2014 Discontinued - Preclinical for Breast cancer in New Zealand (Parenteral)